Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations

Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome

(2018) Zubin Punthakee et al.   Canadian Journal of Diabetes

Role of plasminogen activator inhibitor-1 in coronary pathophysiology

(2018) Richard G. Jung et al.   THROMBOSIS RESEARCH

Variability of biomarkers in patients with chronic heart failure and healthy controls

(2016) Wouter C. Meijers et al.   EUROPEAN JOURNAL OF HEART FAILURE

Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies

(2016) James Yarmolinsky et al.   Scientific Reports

The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin

(2015) Søs Neergaard-Petersen et al.   PLoS One

A Comprehensive Review on Metabolic Syndrome

(2014) Jaspinder Kaur   Cardiology Research and Practice

Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle

(2013) F. A. J. L. Scheer et al.   BLOOD

Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD

(2010) Lin Xu et al.   CLINICAL ENDOCRINOLOGY

Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents

(2008) K. M. KATSAROS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin

(2008) Helén Brogren et al.   THROMBOSIS RESEARCH